NeuroSense to Reveal Influential Long-Term Survival Data on PrimeC at Notable ALS Conference NeuroSense Therapeutics Ltd. will present significant long-term survival data from its Phase 2b trial for PrimeC at a prominent ALS conference on March 9, 2026.

NeuroSense to Reveal Influential Long-Term Survival Data on PrimeC at Notable ALS Conference #United_States #Cambridge #ALS_Study #NeuroSense #PrimeC

PTC Therapeutics Unveils Disappointing Findings from CardinALS Trial of Utreloxastat for ALS Treatment PTC Therapeutics announced unfavorable results from the CardinALS study of Utreloxastat, indicating lack of efficacy in ALS treatment, offering insights into the challenges in neurodegenerative disease management.

PTC Therapeutics Unveils Disappointing Findings from CardinALS Trial of Utreloxastat for ALS Treatment #USA #PTC_Therapeutics #Warren #Utreloxastat #ALS_Study